Table V.6

Table V.6: States Reporting Challenges in Communication or Other Interactions with FDA
	Significance of challenges in communication or other interactions with FDA reported by 15 states reporting challenges
	Number of states
Types of communication or interactions with the Food and Drug Administration (FDA) that posed a challenge	Very challenging	Moderately challenging	Slightly challenging	Not at all challenging	Not applicable
Getting FDA to respond to our requests for information	7	7	1	0	0
Scheduling an individual meeting with FDA	2	2	5	3	3
Getting FDA to provide responses to our questions related to oversight of drug compounding	4	6	3	0	2
Getting notification of pharmacy inspections conducted by FDA in our state	2	4	2	6	1
Getting complete information from FDA in Form 483 inspection observation reports on pharmacy inspections conducted by FDA in our state	5	2	3	3	2
Getting FDA approval of our requests for joint inspections of licensed or registered pharmacies in our state^a	2	1	3	1	7
Getting notification from FDA when FDA determines a licensed or registered pharmacy in our state is acting contrary to section 503A of the Federal Food, Drug, and Cosmetic Act	5	3	0	3	4
Getting notification from FDA of FDA enforcement actions taken against licensed or registered pharmacies in our state	3	5	0	3	4

^{Source: GAO survey of state pharmacy regulatory bodies, survey question 33. | GAO-17-363SP}

Notes: GAO surveyed the state pharmacy regulatory bodies in the 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands, and all but 4 completed the survey.

^aOne of the 15 states did not indicate a significance of the challenge related to this type of communication or interaction with FDA.